Corvus Pharmaceuticals, Inc. (CRVS) vs MoonLake Immunotherapeutics (MLTX)
A side-by-side comparison of Corvus Pharmaceuticals, Inc. and MoonLake Immunotherapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRVS
Corvus Pharmaceuticals, Inc.
$10.51HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
MLTX
MoonLake Immunotherapeutics
$11.26HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
Total return — CRVS vs MLTX
growth of $100 · dividends reinvested · last 6yCRVS +165.2% (+17.6%/yr)MLTX +8.5% (+1.4%/yr)CRVS compounded faster over this window
CRVS MLTX
CRVS vs MLTX: by the numbers
- •MLTX is the larger company ($947M vs $884M market cap).
Metrics side by side
Valuation
| Metric | CRVS | MLTX |
|---|---|---|
| P/B ratio | 3.92 | 2.21 |
Profitability
| Metric | CRVS | MLTX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -24.02% | -61.58% |
| ROIC | -25.25% | -50.77% |
Growth (annualized)
| Metric | CRVS | MLTX |
|---|---|---|
| Total return CAGR (5Y) | 17.88% | 2.81% |
Frequently asked
- How have CRVS and MLTX total returns compared?
- Over the past 5 years, CRVS delivered 17.88% and MLTX delivered 2.81% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.